Treatment of Operable Small Cell Lung Cancer, Limited Stage I–IIA (T1–2, N0, M0)

Clinical Scenario

This protocol covers patients with small cell lung cancer (SCLC) at clinical stage I–IIA: tumours classified T1–2 with no regional nodal involvement (N0) and no distant metastases (M0), confirmed through comprehensive staging. Pathologic lymph node staging is negative and the patient is considered operable.

SCLC Limited Stage Stage I–IIA T1–2, N0, M0 Operable Node-Negative

Staging & Eligibility

Patients most likely to benefit from surgery are those with SCLC at clinical stage I–IIA after standard staging evaluation — including CT of the chest and upper abdomen, brain imaging, FDG-PET/CT, and lymph node staging. Limited stage encompasses disease that can be safely treated with definitive radiation doses (Stage I–III, any T, any N, M0); this subset is specifically operable and pathologically node-negative.

Treatment Approach (Partial Overview)

The preferred surgical approach is lobectomy with mediastinal lymph node dissection or systematic lymph node sampling. Following resection, the course of adjuvant systemic therapy is determined by the nodal findings at surgery — whether the resection was complete and whether nodes were involved. Margin status at resection further shapes the subsequent treatment path.

Full regimen details, sequencing, decision points, and all clinical options are in the complete protocol.

Treatment Goals

The primary aim is complete response or partial response of disease on imaging after completion of adjuvant therapy.

Instant Access to Structured Evidence-Based Regimens

References

Patients most likely to benefit from surgery are those with SCLC that is clinical stage I–IIA (T1–2,N0,M0) after standard staging evaluation (including CT of the chest and upper abdomen, brain imaging, FDG-PET/CT imaging, and lymph node staging).

Limited stage: Stage I-III (T any, N any, M0) that can be safely treated with definitive radiation doses.

For patients undergoing definitive surgical resection, the preferred operation is lobectomy with mediastinal lymph node dissection or systematic lymph node sampling (eg, ≥3 N2 and ≥1 N1 stations).

Patients who undergo complete resection should be treated with postoperative systemic therapy.

Patients without nodal metastases should be treated with systemic therapy alone.

Patients with N2 or N3 nodal metastases should be treated with postoperative concurrent or sequential systemic therapy and mediastinal RT.

View source ↗